Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8461804 | 0.84 | TP53 (0.32) | TSHRALDH1A1TP53 | |
| SCHEMBL9555431 | 0.78 | ALDH1A1 (0.36) | TSHRALDH1A1TP53CYP2C19 | |
| SCHEMBL20530250 | 0.77 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8459467 | 0.77 | — | — | |
| SCHEMBL26939982 | 0.77 | TSHR (0.40) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL24496434 | 0.74 | LMNA (0.30) | — | |
| SCHEMBL8460210 | 0.74 | — | — | |
| SCHEMBL27928595 | 0.74 | — | — | |
| SCHEMBL9127789 | 0.74 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL52160 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2652050-B1 | WATERBORNE COATING COMPOSITIONS THAT INCLUDE 2,2,4-TRIMETHYL-3-OXOPENTANOATE ESTERS AS REACTIVE COALESCENTS | EASTMAN CHEM CO (US) | 2018-10-17 | — | — | EP | claimed |
| US-9029451-B2 | Waterborne coating compositions that include 2,2,4-trimethyl-3-oxopentanoate esters as reactive coalescents | EASTMAN CHEMICAL COMPANY (US) | 2015-05-12 | — | — | US | claimed |
| EP-2652050-A1 | WATERBORNE COATING COMPOSITIONS THAT INCLUDE 2,2,4-TRIMETHYL-3-OXOPENTANOATE ESTERS AS REACTIVE COALESCENTS | Eastman Chemical Company (US) | 2013-10-23 | — | — | EP | claimed |
| US-20120157614-A1 | WATERBORNE COATING COMPOSITIONS THAT INCLUDE 2,2,4-TRIMETHYL-3-OXOPENTANOATE ESTERS AS REACTIVE COALESCENTS | EASTMAN CHEMICAL COMPANY (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082512-A1 | WATERBORNE COATING COMPOSITIONS THAT INCLUDE 2,2,4-TRIMETHYL-3-OXOPENTANOATE ESTERS AS REACTIVE COALESCENTS | EASTMAN CHEMICAL COMPANY (US) | 2012-06-21 | — | — | WO | claimed |
| US-20230400766-A1 | ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-4213238-A1 | ALL-SOLID-STATE BATTERY | Samsung SDI Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20230223591-A1 | ALL-SOLID-STATE BATTERY | SAMSUNG SDI CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| EP-2652050-B1 | WATERBORNE COATING COMPOSITIONS THAT INCLUDE 2,2,4-TRIMETHYL-3-OXOPENTANOATE ESTERS AS REACTIVE COALESCENTS | EASTMAN CHEM CO (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| CN-103237851-B | Including 2,2,4 trimethyl 3 oxopentanoic acid esters as the water-based paint compositions of coalescence reactive agent | 伊士曼化工公司 | 2016-12-21 | — | — | CN | disclosed |
| EP-2385034-B1 | Process for the preparation of 1-nitro-4-oxobutanylamides | SYNKOLA S R O (SK) | 2015-12-02 | — | — | EP | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-3992361-A | Method for producing anionic polyamides with chemically bonded dye | CESKOSLOVENSKA AKADEMIE VED (CS) | 1976-11-16 | — | — | US | disclosed |
| US-3971816-A | Esters of carboxylic acids formally substituted by sodium or potassium in the alpha-position and the method for their preparation | CESKOSLOVENSKA AKADEMIE VED (CS) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TSHR 4691/4885ALDH1A1 2369/4885TP53 368/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | TSHR 3110/4885ALDH1A1 3037/4885TP53 1598/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TSHR 4691/4885ALDH1A1 2369/4885TP53 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.